Guidance II Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Guidance II

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: 2MAR$ who wrote (1872)	1/11/2014 12:20:06 PM
From: 2MAR$	Read Replies (1) of 2077

Large Cap Gainers INFY (59.14 +5.33%): Reported Q3 EPS of INR 50.32, INR 3.58 better than INR 46.74 estimate, revs rose 24.9% yoy to INR 130.23 bln vs INR 130.01 estimate; sees FY14 revs of INR 502-504 bln vs INR 501.86 bln estimate UAL (45.57 +4.04%): Price target raised to $49 from $42 at Imperial Capital; continued strength on strong December operating metrics ORAN (12.87 +3.32%): Hearing reports that AT&T and Deutsche Telekon may make a bid for the company Large Cap Losers AA (10.14 -5.14%): Missed quarterly EPS by $0.02 ($0.04 ex items vs $0.06 estimate), revs fell 5.3% yoy to $5.59 bln vs $5.38 bln estimate GIB (31.64 -2.68%): Obama administration terminating co's contract for HealthCare.gov CVX (120.48 -2.28%): Issued interim update for Q4 2013: earnings expected to be comparable with prior year; U.S. net oil-equivalent production was lower, primarily due to planned downtime across multiple assets in the Gulf of Mexico Mid Cap Gainers ICPT (443.61 +60.8%): Continued strength following announcement that the FLINT trial of obeticholic acid (OCA) for the treatment of nonalcoholic steatohepatitis (NASH) has been stopped early for efficacy; price target raised to $872 from $81 at BofA/Merrill ANF (36.72 +10.56%): Sees FY14 EPS of $1.55-1.65 (raised from $1.40-1.50) vs $1.48 estimate; upgraded to Buy from Neutral at Janney, price targe raised to $49 from $34 AYI (131.52 +6.49%): Upgraded to Neutral from Underperform at Webush, target raised to $120 from $57; target raised to $128 from $100 at Cantor Fitzgerald Mid Cap Losers NRP (17.03 -16.26%): Declared Q4 dividend of $0.35 vs $0.55 in prior quarter; reaffirmed FY13 revs of $330-360 mln vs $347.37 mln estimate, EPS of $1.40-1.60 vs $1.47 estimate); sees FY14 revs of $305-340 mln vs $362.62 mln estimate, EPS of $1.10-1.30 vs $1.57 estimate MNKD (6.1 -13.84%): Co announced that the FDA's Endocrinologic and Metabolic Drugs Advisory Committee is tentatively scheduled on April 1, 2014 to review MannKind's NDA for AFREZZA Inhalation Powder; analysts at MLV & Co note that this introduces a new element of risk SHLD (36.99 -13.11%): Sees Q4 EPS of -$2.98 to -$2.01 ex items vs -$0.12 estimate; total domestic comparable sales for the quarter-to-date period declined 7.4%

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next